Compare Stocks → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:CRDFNASDAQ:LIFENASDAQ:TROVNASDAQ:TTNP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$12.50+5.0%$14.38$8.98▼$24.20$15.50M1.413,753 shs1,916 shsCRDFCardiff Oncology$5.26-8.5%$2.81$0.94▼$6.42$235.02M1.721.66 million shs562,295 shsLIFEaTyr Pharma$1.93-3.8%$1.79$1.08▼$2.70$130.42M1.25549,337 shs592,500 shsTROVCardiff Oncology$5.75+6.7%$16.75$0.70▼$3.46$63.31M1.04648,892 shs1.77 million shsTTNPTitan Pharmaceuticals$6.95-5.8%$6.97$5.00▼$16.90$5.21M1.3412,826 shs8,878 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics-1.57%-5.59%-17.58%-17.98%+1.85%CRDFCardiff Oncology+6.68%+15.93%+236.26%+296.55%+278.29%LIFEaTyr Pharma+4.44%-0.99%+3.09%+36.05%-7.41%TROVCardiff Oncology-2.71%+15.93%+244.31%+278.29%+293.84%TTNPTitan Pharmaceuticals+0.14%+6.73%-8.88%+10.45%-50.08%Urgent: Protect Your Investments from a Chinese Invasion (Ad)An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACRDFCardiff Oncology1.1186 of 5 stars3.52.00.00.02.80.00.0LIFEaTyr Pharma1.967 of 5 stars3.43.00.00.03.01.70.0TROVCardiff OncologyN/AN/AN/AN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/ACRDFCardiff Oncology3.00Buy$10.5099.62% UpsideLIFEaTyr Pharma2.75Moderate Buy$23.671,129.44% UpsideTROVCardiff OncologyN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest TROV, ACOR, LIFE, TTNP, and CRDF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.003/6/2024CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $14.003/1/2024CRDFCardiff OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $7.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$118.57M0.13N/AN/A$77.13 per share0.16CRDFCardiff Oncology$490K479.63N/AN/A$1.56 per share3.37LIFEaTyr Pharma$350K372.63N/AN/A$1.54 per share1.25TROVCardiff Oncology$250K253.25N/AN/A$0.94 per share6.12TTNPTitan Pharmaceuticals$560K9.31N/AN/A$1.86 per share3.74Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$65.92M-$17.11N/A∞N/A-14.35%-21.45%-4.25%4/1/2024 (Confirmed)CRDFCardiff Oncology-$41.44M-$0.93N/AN/AN/A-8,492.01%-50.13%-44.31%5/2/2024 (Estimated)LIFEaTyr Pharma-$50.39M-$0.96N/AN/AN/AN/A-49.84%-39.12%5/14/2024 (Estimated)TROVCardiff Oncology-$16.41M-$2.80N/A∞N/A-3,688.31%-202.00%-122.92%N/ATTNPTitan Pharmaceuticals-$10.21MN/A0.00∞N/A-2,021.31%-302.61%-144.74%4/2/2024 (Estimated)Latest TROV, ACOR, LIFE, TTNP, and CRDF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024N/AACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/A 2/29/2024Q4 2023CRDFCardiff Oncology-$0.26-$0.21+$0.05-$0.21$0.08 million$0.16 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.071.591.21CRDFCardiff OncologyN/A7.417.41LIFEaTyr Pharma0.026.276.27TROVCardiff Oncology0.122.372.37TTNPTitan PharmaceuticalsN/A5.305.30OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%CRDFCardiff Oncology16.29%LIFEaTyr Pharma61.72%TROVCardiff Oncology9.99%TTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%CRDFCardiff Oncology6.30%LIFEaTyr Pharma3.14%TROVCardiff Oncology0.60%TTNPTitan Pharmaceuticals24.93%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataCRDFCardiff Oncology3144.68 million41.86 millionOptionableLIFEaTyr Pharma6567.75 million65.62 millionOptionableTROVCardiff OncologyN/A11.01 millionN/ANot OptionableTTNPTitan Pharmaceuticals4750,000565,000OptionableTROV, ACOR, LIFE, TTNP, and CRDF HeadlinesSourceHeadline2005 Nissan Titanautoblog.com - March 25 at 4:09 AMTitan Pharmaceuticals (NASDAQ:TTNP) Share Price Passes Below Two Hundred Day Moving Average of $7.56americanbankingnews.com - March 22 at 4:42 AMStockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)americanbankingnews.com - March 22 at 2:17 AMTitan Pharmaceuticals Inc (TTNP)uk.investing.com - March 2 at 9:17 AMTitan Pharmaceuticals, Inc. (TN70.F)au.finance.yahoo.com - February 20 at 2:08 PMTitan Pharmaceuticals Inc TTNPmorningstar.com - February 3 at 2:27 PMTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteriafinanznachrichten.de - January 26 at 9:07 PMTitan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteriafinance.yahoo.com - January 25 at 7:32 PMTitan Pharma Stock (NASDAQ:TTNP) Dividends: History, Yield and Datesbenzinga.com - January 10 at 1:05 PMTitan Pharmaceuticals: Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibitscbonds.com - December 30 at 10:29 AMTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Reverse Stock Split and Ratiofinanznachrichten.de - December 29 at 8:01 AMBarbie, the Titan submersible and everything else we Googled in 2023washingtonpost.com - December 28 at 8:29 PMTitan Pharmaceuticals Announces Reverse Stock Split and Ratiofinance.yahoo.com - December 28 at 8:29 PMUntitled Attack on Titan Codes (December 2023)twinfinite.net - December 27 at 3:54 PM2023 Nissan Titan XD Reviewautoblog.com - December 27 at 3:54 PMAttack on Titan Revolution Codes (December 2023)twinfinite.net - December 20 at 10:44 PMTitan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directorsfinance.yahoo.com - October 16 at 8:58 PMMore presumed human remains recovered from imploded Titan submersibletoday.com - October 14 at 10:10 AMTitan Pharmaceuticals reports $9.5M private placement of convertible preferred stockseekingalpha.com - September 18 at 11:34 AMTitan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stockfinance.yahoo.com - September 18 at 11:34 AMUnveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guidefinance.yahoo.com - August 28 at 5:04 PMTitan Pharmaceuticals: Q2 Earnings Snapshotstamfordadvocate.com - August 15 at 5:27 PMTitan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approvalthestreet.com - August 13 at 6:28 PMTitan Pharmaceuticals sells certain ProNeura assets to Fedsonpharmabiz.com - July 29 at 5:54 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple WaysHims & Hers Stock Rises On Stimulating Earnings GrowthMarch 5, 2024 6:05 AMView Hims & Hers Stock Rises On Stimulating Earnings Growth3 Real Estate Stocks to Buy on Commission CutsMarch 20, 2024 6:15 AMView 3 Real Estate Stocks to Buy on Commission CutsLifeMD Shares Come Back to Life on GLP-1 Business Growth March 19, 2024 6:05 AMView LifeMD Shares Come Back to Life on GLP-1 Business Growth Lyft Resets the Stage For Its Path to Profitability March 10, 2024 2:48 PMView Lyft Resets the Stage For Its Path to Profitability All Headlines Company DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Cardiff OncologyNASDAQ:CRDFCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.Cardiff OncologyNASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.Titan PharmaceuticalsNASDAQ:TTNPTitan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.